Life stage differences in mammary gland gene expression profile in non-human primates by Stute, Petra et al.
PRECLINICAL STUDY
Life stage differences in mammary gland gene expression profile
in non-human primates
Petra Stute • Sonja Sielker • Charles E. Wood • Thomas C. Register •
Cynthia J. Lees • Fitriya N. Dewi • J. Koudy Williams •
Janice D. Wagner • Ulrich Stefenelli • J. Mark Cline
Received: 14 August 2011 / Accepted: 28 September 2011 / Published online: 25 October 2011
 Springer Science+Business Media, LLC. 2011
Abstract Breast cancer (BC) is the most common
malignancy of women in the developed world. To better
understand its pathogenesis, knowledge of normal breast
development is crucial, as BC is the result of disregulation
of physiologic processes. The aim of this study was to
investigate the impact of reproductive life stages on the
transcriptional profile of the mammary gland in a primate
model. Comparative transcriptomic analyses were carried
out using breast tissues from 28 female cynomolgus
macaques (Macaca fascicularis) at the following life
stages: prepubertal (n = 5), adolescent (n = 4), adult
luteal (n = 5), pregnant (n = 6), lactating (n = 3), and
postmenopausal (n = 5). Mammary gland RNA was
hybridized to Affymetrix GeneChip Rhesus Macaque
Genome Arrays. Differential gene expression was analyzed
using ANOVA and cluster analysis. Hierarchical cluster
analysis revealed distinct separation of life stage groups.
More than 2,225 differentially expressed mRNAs were
identified. Gene families or pathways that changed across
life stages included those related to estrogen and androgen
(ESR1, PGR, TFF1, GREB1, AR, 17HSDB2, 17HSDB7,
STS, HSD11B1, AKR1C4), prolactin (PRLR, ELF5,
STAT5, CSN1S1), insulin-like growth factor signaling
(IGF1, IGFBP1, IGFBP5), extracellular matrix (POSTN,
TGFB1, COL5A2, COL12A1, FOXC1, LAMC1, PDG-
FRA, TGFB2), and differentiation (CD24, CD29, CD44,
CD61, ALDH1, BRCA1, FOXA1, POSTN, DICER1,
LIG4, KLF4, NOTCH2, RIF1, BMPR1A, TGFB2). Preg-
nancy and lactation displayed distinct patterns of gene
expression. ESR1 and IGF1 were significantly higher in the
adolescent compared to the adult animals, whereas differ-
entiation pathways were overrepresented in adult animals
and pregnancy-associated life stages. Few individual genes
were distinctly different in postmenopausal animals. Our
data demonstrate characteristic patterns of gene expression
during breast development. Several of the pathways acti-
vated during pubertal development have been implicated in
cancer development and metastasis, supporting the idea
that other developmental markers may have application as
biomarkers for BC.
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PDGFRA Platelet-derived growth
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of transcription 5
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TGFB2 Transforming growth factor, beta-2
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Introduction
Major determinants of breast cancer (BC) risk include age,
genetics, and reproductive history. Timing of reproductive
milestones such as age at menarche and menopause,
pregnancy, and lactation has an impact on breast devel-
opment and thereby may alter the risk of developing BC
later in life. Therefore, the study of breast development and
differentiation across the lifespan may shed light on the
origins of BC.
Mammary gland development may be separated into
embryonic, adolescent, and adult phases, each of which is
differentially regulated [1–4]. Embryonic branching of the
breast is thought to occur without any hormonal require-
ment as it is not impaired in the absence of ER-alpha
(ERa), ER-beta (ERb), progesterone receptor (PGR), or the
receptors for growth hormone (GH) or prolactin (PRLR).
During adolescent branching, GH, insulin-like growth
factor (IGF)-1, and ovarian estrogens as well as ERa are
crucial; adult tertiary side-branching requires progesterone
and its receptor [5].
All epithelial cells in the mammary gland are thought to
originate from a common stem cell [6]. During differenti-
ation from ERa negative stem cells to ERa positive pro-
genitor cells and consecutively to basal- or luminal-
restricted progenitors, these cells express different cell
surface markers. Although unique stem cell markers have
proven difficult to define, patterns of protein expression can
distinguish mammary epithelial cells with stem-like or
progenitor-like characteristics [7, 8].
As stem cells are undifferentiated and relatively resistant
to apoptosis they may accrue DNA damage and mutations,
making them susceptible to cancer initiation [9, 10]. The
stem cell model of carcinogenesis proposes that BC
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originates in tissue stem or progenitor cells probably
through deregulation of self-renewal pathways, resulting in
BC cells with the defining stem cell properties of self-
renewal and differentiation. Self-renewal drives tumori-
genesis, whereas differentiation contributes to tumor phe-
notypic heterogeneity [11].
To investigate the impact of reproductive stages and
their respective characteristic hormonal profiles on mam-
mary gene expression in the human breast, one would have
to take breast biopsies from healthy girls and women
without any exogenous hormonal exposure such as hor-
monal contraception, fertility drugs, or postmenopausal
hormone therapy. This is practically and ethically impos-
sible. A unique model for studying these questions is the
monkey model. Female cynomolgus macaques (Macaca
fascicularis) have distinctive reproductive similarities to
women, including a 28-day menstrual cycle, comparable
ovarian hormone patterns, and natural ovarian senescence.
Macaques have [95% overall genetic sequence identity to
humans, including key genes involved in BC susceptibility
[12]. Human and macaque mammary glands are similar in
terms of microanatomy and development, sex steroid
receptor expression, responses to exogenous hormones, and
the development of a heterogeneous spectrum of hyper-
plastic and neoplastic lesions with aging [13–15].
The aim of this study was to identify the impact of
reproductive stages and their respective characteristic
hormonal profiles on normal breast development by com-
paring gene expression patterns of the mammary gland
from young animals (prepubertal and adolescent), adults
(premenopausal in luteal cycle phase and postmenopausal),
and animals in pregnancy-associated life stages (pregnancy
and lactation) in cynomolgus monkeys. By gaining a better
understanding of breast development, we also aimed to
identify new biomarkers of BC that might proceed to new
approaches in targeted therapies.
Methods
Animal characteristics and life stage selection
Healthy control female cynomolgus macaques (Macaca
fascicularis) were imported from the Institut Pertanian
Bogor (Bogor, Indonesia). Diets fed were nutritionally
complete for non-human primates, free of soy isoflavones,
and providing 42% of calories from fat in order to model
the North American diet. Animals were housed in social
groups of at least 4 animals. All procedures were approved
by the Institutional Animal Care and Use Committee
(IACUC) of the Wake Forest University School of
Medicine, which is accredited by the Association for the
Advancement and Accreditation of Laboratory Animal
Care. The animals (total n = 28) were selected from four
life stage groups: prepubertal (n = 5), adolescent (n = 4),
adult luteal (n = 5), pregnant (n = 6), lactating (n = 3),
and postmenopausal (n = 5). Ages were determined by
dental eruption or known birth dates. Serum estradiol and
progesterone levels were determined in the Yerkes Assay
Services laboratory, Yerkes National Primate Research
Center. Prepubertal and adolescent animals were of similar
estimated age; the prepubertal stage was defined retro-
spectively, as referring to a sample taken more than
6 months prior to menarche. Adolescent animals were
defined by menarche having occurred recently (within the
preceding 6 months). Monkeys at adult luteal stage were in
the luteal phase of the menstrual cycle, which was defined
by endometrial and ovarian histology at necropsy. Pregnant
monkeys were in the third trimester of gestation. Post-
menopausal monkeys had undergone oophorectomy, which
was performed at least 2.5 years prior to necropsy. Stages
of breast development were confirmed by histopathology,
using characteristics we have described previously [14, 16].
Tissue collection
Mammary gland, including associated fat and connective
tissues, was collected either by breast biopsy or at nec-
ropsy. All prepubertal and adolescent samples and one
sample from a lactating animal were collected by biopsy.
Necropsy samples were only taken from animals from
which they could be collected quickly (within 5 min of
preplanned euthanasia). For biopsies, animals were anes-
thetized with ketamine (10–15 mg/kg) and buprenorphine
(0.01 mg/kg), a 1.5-cm incision was made in the upper
outer breast quadrant, and a small (0.4 gram) sample of
mammary gland was removed. Biopsies were performed by
an experienced veterinary surgeon. The incision was
sutured, and the animals were monitored and given anal-
gesia during recovery following IACUC-approved clinical
procedures. Half of the biopsy sample was frozen; the other
half was fixed at 4C in 4% paraformaldehyde for 24 h,
transferred to 70% ethanol, and then processed for histol-
ogy using standard procedures. For necropsy samples,
euthanasia was performed as part of unrelated IACUC-
approved experimental protocols. Mammary tissues, ova-
ries, and uteri were removed, and fixed and frozen samples
were collected as above. Each breast sample used for gene
microarray analysis was evaluated by histology and
mammary whole mount analysis to assure the presence of
epithelial tissue with typical morphology for each devel-
opmental stage [17].
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Gene microarray assays
Total RNA was extracted from frozen mammary samples
using Tri Reagent (Molecular Research Center, Cincinnati,
OH), purified using an RNeasy Mini kit (Qiagen, Valencia,
CA, USA), and quantified using a Nanodrop ND-100 UV–
VIS spectrophotometer (NanoDrop, Wilmington, DE).
RNA intactness and quality were confirmed using an Ag-
ilent 2100 Bioanalyzer (Wilmington, DE). Only samples
with an RNA integrity number (RIN) greater than 8.0 were
used for hybridization. One microgram of total RNA from
each sample was labeled using the GeneChip One-Cycle
Target Labeling kit (Affymetrix, Inc., Santa Clara, CA)
following the manufacturer’s protocol. RNA was then
fragmented and hybridized to GeneChip Rhesus Macaque
Genome Arrays (Affymetrix, Inc., Santa Clara, CA) for
17 h, prior to washing and scanning. Data were extracted
from scanned images using GeneChip Operating Software
(Affymetrix, Inc., Santa Clara, CA). RNA quality control
and microarray assays were performed at Cogenics, a
Division of Clinical Data (Morrisville, NC; http://www.
cogenics.com). One mammary gland sample from the
prepubertal life stage group did not yield sufficient RNA
for hybridization and was excluded, bringing the total
number of arrays to 27 and the subset number of prepu-
bertal animals to four.
Quantitative RT-PCR
RNA was reverse-transcribed using a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA). Transcript levels for targets related to estrogen,
androgen, and prolactin metabolism were measured using
quantitative real-time polymerase chain reaction (qRT-
PCR). Cynomolgus macaque, rhesus macaque, or human
ABI Taqman primer probe assays were used as targets, and
samples were normalized to endogenous GAPDH and
ACTB using cynomolgus macaque-specific primer probes.
Stock macaque mammary tissues and macaque BC tumors
were run in triplicate on each plate as external calibrators.
Reactions were performed with ABI PRISM 7500 Fast
Sequence Detection System (Applied Biosystems), and
relative expression was determined using the DDCt method
calculated by ABI Relative Quantification 7500 Software
v2.0.1.
Statistics
Microarray data analyses were performed using the Ge-
neSifter software program (VizX Labs LLC, Seattle, WA,
USA; http://www.genesifter.net). Intensity data were con-
verted to a log2 scale, screened for heterogeneity among
samples, and evaluated using supervised analysis of
variance (ANOVA) and pairwise comparisons between
treatments. Principal components analysis (PCA), pattern
navigation, and cluster analysis were performed on data
subsets filtered by expression threshold. All P values were
corrected for multiple comparisons using the Benjamini
and Hochberg method (Padj) [18], which derives a false
discovery rate estimate from the raw P values [19]. Dif-
ferences in gene numbers altered by each treatment were
compared using a Fisher’s exact test.
Quantitative RT-PCR data were analyzed using JMP
(version 8.0.2, SAS Institute, Cary, NC). All relative
expression data were evaluated for normality and homo-
geneity of variances among groups. Data were log-trans-
formed and evaluated using ANOVA or the Kruskal–
Wallis non-parametric test, then retransformed to original
scale, and reported as fold change in prepubertal (control)
group with 95% confidence interval. Multiple comparisons
were made using Student’s T-test for each pair, with two-
tailed significance level of 0.05.
Results
Animal characteristics and tissue histology
Characteristics of animals in the study are presented in
Table 1. Breast tissue of prepubertal animals consisted
primarily of immature ducts and terminal end buds. Adult-
type lobular units were present in all other life stages;
pregnant animals were distinguished by marked lobular
proliferation, and lactating animals by pronounced secre-
tory activity. Representative histologic images of the breast
tissue at each life stage are shown in Fig. 1, including
immunohistochemistry for the proliferation marker Ki67.
Global gene expression profiles
Principal components analysis and hierarchical clustering
were initially used to evaluate mammary gland gene
expression patterns across life stages (Fig. 2). Overall,
26,481 probe sets were detected at a quality [2 and
threshold fold change (FC) [1.5. Among these probes,
PCA showed divergent vectors for juvenile animals (pre-
pubertal and adolescent), pregnancy-associated life stages
(pregnant and lactating), and adult animals (adult luteal and
postmenopausal). Corresponding clustering dendrograms
showed clear separation of all groups, with closer associ-
ations between the following groups: prepubertal and
adolescent; pregnant and lactating; and adult luteal and
postmenopausal.
Overall, 1,964 significantly differentially expressed
probe sets were identified (ANOVA Padj \ 0.05) for which
FC [ 1.2. The overall pattern of gene expression by PCA
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was similar regardless of the threshold for FC [ 1.2, 2.0
and 3.0 at Padj \ 0.05 for young animals. However, among
the adult groups at higher FC, pregnant animals diverged
from lactating animals and were more closely associated
with adult luteal animals.
Most genes contributing to the difference between
juvenile and adult animals were expressed in common by
adult luteal, pregnant, and postmenopausal groups. How-
ever, most genes expressed by lactating animals were not
shared by other groups. Between the two juvenile groups,
no genes differed at a threshold of FC [ 10, and there were
only 137 differentially expressed genes at a threshold [1.8
(Padj \ 0.05). Adult groups showed similar overall direc-
tional patterns in gene expression changes, but each dif-
fered in the number of transcripts altered from prepubertal
subjects and the magnitude of gene expression changes.
For example, adult luteal and postmenopausal profiles
resulted in 60 (37 up-regulated and 23 down-regulated) and
55 (36 up-regulated and 19 down-regulated) altered tran-
scripts relative to the prepubertal profile with FC [ 10,
respectively. Even more differences in the number of
altered transcripts were apparent when comparing preg-
nancy-associated life stages versus prepubertal profiles
with FC [ 10 revealing 136 differences in pregnant
animals (59 up-regulated and 77 down-regulated) and 437
differences in lactating animals (109 up-regulated and 328
down-regulated). Adult differences from the prepubertal
group are shown graphically in Fig. 3.
Ten genes were regulated in common in all adult life
stage groups and differed from prepubertal animals at
threshold [10 and Padj \ 0.05 (Table 2). Among these
differentially expressed genes, those associated with
estrogen-regulated processes, proliferation, adhesion, and
survival (TFF1, GREB1, NEK10, LRRN3, PPM1K, PGR,
IGFBP1) decreased with advancing age, reaching their
lowest levels during adult luteal phase (IGFBP1), preg-
nancy (TFF1, NEK10, PPM1K, LRRN3), lactation (PGR),
and postmenopause (GREB1), respectively. Pairwise
comparisons of gene expression between all groups
revealed significant differences between prepubertal ani-
mals and all adult groups except postmenopausal. Among
the four adult premenopausal life stage groups, significant
differences were found for mammary LRRN3, GREB1,
PPM1K, NEK10, and PGR gene expression (Padj B 0.05).
LRRN3 expression was significantly lower in pregnant than
in postmenopausal breast tissue. PGR expression was sig-
nificantly lower in lactating than in pregnant and adult
luteal breast tissue. GREB1 expression was lower in
Table 1 Characteristics of animals in the study
Group N Age (year) Body weight (kg) Estradiol (pg/ml) Progesterone (ng/ml)
Prepubertal 4 2.8a 1.9 ± 0.1 12.3 ± 8.5 1.1 ± 0.7
Adolescent 4 2.8b 2.2 ± 0.3 4.6 ± 2.4 0.9 ± 0.7
Adult (luteal phase) 5 13.2 ± 5.8 3.5 ± 0.5 23.2 ± 15.6 2.2 ± 0.7
Pregnant 6 10.4 ± 2.8 3.3 ± 0.7 373.1 ± 151.3* 5.2 ± 0.6*
Lactating 3 8.1 ± 1.8 3.8 ± 2.0 8.6 ± 0.6 1.5 ± 1.0
Postmenopausal 5 18.4 ± 3.7 3.5 ± 0.9 3.1 ± 0.0 0.7 ± 0.7
Data are means ± standard deviation. Ages are estimated based on dentition
* Different from all other groups at P \ 0.05 (Tukey’s HSD test)
a Sample collected greater than 6 months before menarche
b Sample collected within 6 months after menarche
Fig. 1 Photomicrographs of breast histology for each life stage studied. Objective magnification was the same (940) for all images.
Immunohistochemical stain for the proliferation marker Ki67; hematoxylin counterstain
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lactating animals than in pregnant animals. Conversely,
PPM1K and NEK10 gene expression were significantly
lower in pregnant than in lactating breast tissue.
In contrast, the expression of three genes associated with
glandular differentiation (CSN1S1, IGHG1, and ELF5) was
significantly increased with advancing age when compared
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prepubertal animals at threshold
fold change [10 and
Padj \ 0.05. There are no genes
in the adolescent group falling
into this category
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with prepubertal life stage, reaching their maximum during
the luteal phase of the menstrual cycle (IGHG1) or lacta-
tion (CSN1S1, ELF5), respectively (Padj B 0.05). Pairwise
comparisons of differentiation gene expression revealed a
significant difference between prepubertal and adult pre-
menopausal or pregnancy-associated life stages
(Padj B 0.05), but again, not for postmenopausal subjects.
The differentiation markers CSN1S1 and ELF5 peaked
during lactation, differing from all other groups including
pregnant mammary gland (Padj B 0.05). Postmenopausal
mammary ELF5 expression was significantly decreased
when compared with the adult luteal and pregnancy-asso-
ciated life stages (Padj B 0.05).
A secondary goal of this study was to identify signaling
pathways that are significantly altered across life stages
(threshold [ 1.5; ANOVA Padj \ 0.00001). Overall, 4,962
differently regulated genes covering 10 KEGG pathways
and 23 relevant gene ontology cohorts were identified. We
focused on pathways related to androgen and estrogen
metabolism, mammary stem cells, and profiles relevant for
BC development.
Sex steroid receptors and steroid metabolism
Gene expression differences by array for the major recep-
tors of the estrogen, progesterone, prolactin, and androgen
(ESR1, PGRB, PRLR, AR), and key enzymes in steroid
metabolism are shown in Table 3. ESR1 and PGRB
decreased in the transition from prepuberty to adolescence,
and AR gene expression was maximal during adolescence
after which it significantly decreased (Padj B 0.05). ESR1
expression had its minimum during postmenopause,
whereas AR and most strikingly PGRB expression were
lowest during lactation. Lower gene expression for ESR1,
PGRB, and AR during lactation was significant relative to
other life stages (Padj B 0.05). PGRB was less than \1/
100th of prepubertal levels during lactation. Expression of
PRLR significantly increased with maturity in comparison
Table 2 Gene expression microarray data
Prepubertal
(a)
Adolescent
(b)
Adult luteal
(c)
Pregnant
(d)
Lactating
(e)
Postmenopausal
(f)
Pairwise comparisons
Padj \ 0.05
CSN1S1 1.00 2.40 35.54 43.76 101.24 22.66 a vs. c-f
b vs. c-e
e vs. c, d
ELF5 1.00 1.22 10.59 9.16 12.87 2.35 a, b, f vs. c-e
GREB1 1.00 -1.42 -13.58 -12.76 -27.89 -29.17 a vs. c-f
b vs. c-e
d vs. e
IGFBP1 1.00 1.34 -89.23 -86.31 -83.32 -19.67 a vs. c-f
b vs. c-e
IGHG1 1.00 1.11 42.67 36.76 15.45 34.62 a vs. c-f
b vs. c-e
c vs. e
LRRN3 1.00 -1.57 -18.72 -23.83 -16.31 -16.24 a vs. c-f
b vs. c-e
d vs. f
NEK10 1.00 -1.43 -14.73 -30.99 -14.18 -10.09 a vs. c-f
b vs. c-e
d vs. e
PGR 1.00 -1.02 -8.95 -23.77 -112.26 -15.81 a vs. c-f
b vs. c-e
e vs. c, d, f
PPM1K 1.00 -1.74 -12.21 -12.53 -7.08 -12.44 a vs. c-f
b vs. c-e
d vs. e
TFF1 1.00 1.16 -84.59 -168.88 -97.09 -57.84 a vs. c-f
b vs. c-e
Fold change in relative expression for adult life stage groups significantly different from prepubertal animals at threshold [10 and Padj \ 0.05.
Prepubertal and adolescent groups do not differ from each other
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with the prepubertal life stage, reaching its maximum
during pregnancy where it was significantly higher than in
lactating and postmenopausal breast (Padj B 0.05).
Five genes involved in C21, C19, and C18 steroid for-
mation were differently expressed relative to prepubertal
gene profiles (AKR1C4, STS, HSD11B1, HSD17B2, and
HSD17B7; Table 3). AKR1C4 and STS decreased during
the pubertal transition and were lower in all adult groups.
Expression of three genes (STS, HSD11B1, and HSD17B7)
coding for enzymes associated with the formation of more
potent steroid hormones was significantly decreased with
maturity when compared with prepubertal animals, reach-
ing their minimum during pregnancy (HSD11B1,
HSD17B7) and lactation (STS), respectively (Padj B 0.05).
However, for these genes, postmenopausal mammary gene
expression significantly increased to levels comparable to
adolescent and adult luteal life stages for STS, HSD11B1,
and HSD17B7 (Padj B 0.05). Expression of two genes
(HSD17B2 and AKR1C4) coding for enzymes associated
with steroid hormone inactivation to less-potent metabo-
lites was either significantly increased (HSD17B2) or
decreased (AKR1C4) with advancing age when compared
with prepubertal life stage, respectively (Padj B 0.05;
Table 3).
Markers of stem cells and differentiation
Life stage effects on genes related to mammary stem cells
and differentiation were evaluated using gene ontology
analysis (stem cell division n = 9; stem cell differentiation
Table 3 Gene expression array data for sex steroid receptors and metabolism
Prepubertal
(a)
Adolescent
(b)
Adult luteal
(c)
Pregnant
(d)
Lactating
(e)
Postmenopausal
(f)
Pairwise comparisons
Padj \ 0.05
ESR1 1.00 -1.34 -5.01 -4.79 -3.36 -5.10 a vs. b-f
b vs. c-f
c vs. e
PRLR 1.00 1.26 3.20 4.51 1.88 1.61 a vs. b-f
b vs. d
c vs. e
d vs. e, f
PGRB 1.00 -1.02 -8.95 -23.77 -112.26 -15.81 a,b vs. c-f
e vs. c, d, f
AR 1.00 1.33 -2.10 -2.72 -7.54 -1.18 a vs. b-f
b vs. c-e
c vs. e
d vs. e, f
e vs. f
MKI67 1.00 1.06 1.08 1.03 1.18 -1.17 a vs. b-f
c vs. d, e
d vs. e, f
e vs. f
STS 1.00 -1.17 -1.23 -1.31 -1.43 1.32 a vs. b-f
b, c, f vs. d, e
HSD11B1 1.00 1.53 -1.21 -2.04 -1.35 -1.05 a vs. b-f
d vs. b, c, f
HSD17B7 1.00 -1.12 -1.21 -1.84 -1.53 -1.10 a vs. b-f
b, f vs. d, e
c vs. d
HSD17B2 1.00 1.03 4.66 4.92 3.11 3.31 a vs. b-f
b vs. c-e
AKR1C4 1.00 -1.56 -1.34 -2.93 -3.14 -1.52 a vs. b-f
b vs. d
c, f vs. d, e
Up- and down-regulated overlapping genes within life stage groups significantly different from the prepubertal group at P \ 0.05. Pairwise
comparisons at Padj \ 0.05 were made, and the relevant results are presented in the text
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n = 33). Genes differentially regulated at FC [ 1.2 versus
prepubertal (Padj = 0.00001) were initially used for this
analysis (n = 4,955). Herein, 8 genes were found to be
statistically significant (P = 0.001) for stem cell regulation
(DICER1, IGF1, LIG4, KLF4, NOTCH2, RIF1, BMPR1A,
and TGFB2). In addition, we analyzed our data set for gene
expression patterns of stem cell markers presented by La-
Marca and Rosen (ELF5, CD29, CD24, CD61, CD44,
ALDH1, BRCA1, GATA3, FOXA1, STAT5, and POSTN)
[6], and we also included the proliferation marker MKI67
in this category (Table 4).
A distinct pattern of decreased gene expression for
putative stem cell markers and regulators of differentiation
was seen during pregnancy or lactation when compared to
juvenile and adult animals; diminished expression was seen
for DICER1, RIF1, BMPR1A, TGFB2, LIG4, KLF4,
NOTCH2, CD44, FOXA1, and CD29 (Padj B 0.05). In
contrast, mammary gene expression of the differentiation
and stem cell markers ELF5, CD24, STAT5, and ALDH1
increased with advancing age peaking during pregnancy or
lactation (Padj B 0.05). Other potential stem cell markers
presented a heterogeneous gene expression profile across
life stages (KLF4, POSTN, NOTCH2, IGF1, BRCA1, LIG4,
and CD61) with an increase during puberty followed by a
decrease during pregnancy-associated life stages (KLF4,
POSTN, NOTCH2, IGF1, BRCA1, and LIG4) and post-
menopause (POSTN, IGF1, and BRCA1; Padj B 0.05).
MKI67 gene expression remained relatively stable across
life stages.
The luminal progenitor cell population is characterized
by the cell surface marker CD29lo CD24? CD61? and
the differentiated luminal cell population by CD29lo
CD24? CD61-. Pairwise comparisons revealed a signifi-
cant increase in CD24 gene expression in lactating mam-
mary gland in comparison with other life stages, whereas
CD29 gene expression was significantly lower in pregnant
and lactating mammary gland compared to young animals
(Padj B 0.05). CD61 gene expression was significantly
higher in adult luteal and lactating and lower in pregnant
and postmenopausal mammary gland in comparison with
prepubertal subjects (Padj B 0.05). Expression of four
genes associated with cell differentiation, repair mecha-
nisms, and apoptosis (DICER1, RIF1, BMPR1A, and
TGFB2) was significantly decreased with advancing age
when compared with prepubertal animals (Padj B 0.05).
Expression of six genes associated with cell differenti-
ation was significantly increased during adult life stages
when compared with juvenile animals (LIG4, KLF4,
NOTCH2, ELF5, STAT5, ALDH1; Padj B 0.05). Within
adult premenopausal life stages, no significant differences
in expression of DICER1, IGF1, LIG4, KLF4, NOTCH2,
RIF1, BMPR1A, TGFB2, STAT5, or ALDH1 were
observed. Surprisingly, postmenopausal mammary gene
expression did not differ significantly from the adolescent
expression pattern, with the exception of IGF1 gene
expression that was significantly higher during adolescence
than in any other life stage examined (Padj B 0.05). Within
pregnancy-associated life stages, DICER1, IGF1, LIG4,
NOTCH2, STAT5, CD29, BRCA1, and POSTN gene
expression was significantly lower in breast tissue of lac-
tating animals relative to pregnant animals (Padj B 0.05).
The opposite was true for CD24 and CD61 (Padj B 0.05).
Genes DICER1, IGF1, LIG4, NOTCH2, KLF4, RIF1,
BMPR1A, TGFB2, CD29, CD44, FOXA1, BRCA1, and
POSTN exhibited lower expression in lactating compared
to postmenopausal breast tissue (Padj B 0.05). The oppo-
site was true for ELF5, CD24, STAT5, ALDH1, and CD61
gene expression (Padj B 0.05).
Extracellular matrix signaling
Life stage effects on genes related to extracellular matrix
signaling were evaluated using gene ontology analysis
(extracellular matrix organization n = 179). Genes differ-
entially regulated at FC [ 1.2 versus prepubertal
(Padj = 0.00001) were initially used for this analysis
(n = 42). We selected eight significantly differently regu-
lated genes (Table 5).
Overall, gene expression (POSTN, TGFB1, COL5A2,
COL12A1, LAMC1, PDGFRA, TGFB2) was decreased
during all life stages in comparison with prepubertal ani-
mals reaching a nadir during lactation (TGFB1, PDGFRA,
LAMC1, COL12A1, COL5A2; Padj B 0.05). POSTN in
particular was expressed most abundantly in juveniles, with
a tenfold lower expression in cycling or postmenopausal
adults and a 30- to 90-fold lower expression in pregnant
and lactating animals, respectively. However, there was a
significant initial increase in TGFB1, POSTN, and COL5A2
gene expression during adolescence (Padj B 0.05). In
contrast, FOXC1 was significantly up-regulated in adult-
hood in comparison with prepuberty (Padj B 0.05), with
lower expression in lactation.
Breast cancer–associated genes
Next, we selected genes that have been associated with BC
development, described in the 70-gene Amsterdam signa-
ture that forms the basis for the MammaPrint assay [20].
Out of 50 genes represented in the MammaPrint assay, 21
probes were significantly differently regulated at
Padj B 0.05 in our data set, representing six genes
(Table 6).
In general, mammary expression of SERF1A, GTM3,
and PECI genes decreased significantly with advancing age
in comparison with prepubertal life stage, reaching their
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Table 4 Mammary progenitor cell markers
Prepubertal
(a)
Adolescent
(b)
Adult luteal
(c)
Pregnant
(d)
Lactating
(e)
Postmenopausal
(f)
Pairwise comparisons
Padj \ 0.05
ELF5 1.00 1.22 10.59 9.16 12.87 2.35 a, b, f vs. c-e
CD24 1.00 1.09 1.66 1.21 3.97 1.59 a vs. b-f
e vs. b-d, f
STAT5 1.00 1.17 2.81 5.96 1.68 1.14 a vs. b-f
b vs. d
c, f vs. d, e
d vs. e
ALDH1 1.00 1.10 1.38 -1.36 1.47 1.19 a vs. b-f
b vs. d
d vs. e, f
DICER 1.00 -1.23 -1.25 -2.25 -4.02 -1.20 a vs. b-f
b, c vs. d, e
d vs. e, f
e vs. f
RIF1 1.00 -1.37 -1.29 -2.44 -4.49 -1.44 a vs. b-f
b, c vs. d, e
e vs. f
BMPR1A 1.00 -1.12 -1.14 -1.56 -1.56 -1.16 a vs. b-f
b vs. d
c, f vs. d, e
TGFB2 1.00 -1.40 -1.17 -3.99 -6.23 -1.22 a vs. b-f
b, c, f vs. d, e
CD44 1.00 -1.09 -1.30 -2.99 -5.09 -1.15 a vs. b-f
b vs. d, e
c vs. e
CD29 1.00 1.00 -1.24 -1.85 -4.86 -3.86 a vs. b-f
b, c, f vs. d, e
FOXA1 1.00 -1.04 -1.76 -2.28 -2.42 -1.44 a vs. b-f
b, c, f vs. d, e
KLF4 1.00 1.05 1.61 -2.76 -4.19 1.51 a vs. b-f
b vs. c-e
c, f vs. d, e
NOTCH2 1.00 1.17 1.19 -1.58 -2.37 1.11 a vs. b-f
b, c vs. d, e
d vs. e, f
e vs. f
LIG4 1.00 -1.12 1.37 -2.03 -4.09 1.12 a vs. b-f
b vs. c-e
c vs. d, e
d vs. e, f
e vs. f
BRCA1 1.00 1.11 1.06 -1.18 -1.68 -1.22 a vs. b-f
e vs. b-d, f
POSTN 1.00 1.16 -10.06 -28.27 -92.92 -9.17 a vs. b-f
b vs. d-f
c, d vs. e
e vs. f
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minimum during pregnancy (PECI) and lactation
(SERF1A, GTM3), respectively (Padj B 0.05).
However, gene expression of IGFBP5 and TGFB3
revealed a significant increase during adolescence, fol-
lowed by a similar significant decrease in advanced life
stages, also reaching a minimum during lactation
(Padj B 0.05). In contrast, CENPA gene expression was
significantly increased in adolescent, adult luteal, and
pregnant mammary glands when compared with prepu-
bertal subjects and was only significantly decreased during
lactation and postmenopause (Padj B 0.05). Lactating
mammary gland presented a distinct gene expression pat-
tern since pairwise analysis revealed a significant differ-
ence between lactating and young and adult life stages for
Table 5 Extracellular matrix signaling
Prepubertal
(a)
Adolescent
(b)
Adult luteal
(c)
Pregnant
(d)
Lactating
(e)
Postmenopausal
(f)
Pairwise comparisons
Padj \ 0.05
POSTN 1.00 1.16 -10.06 -28.27 -92.92 -9.17 a vs. b-f
b vs. d-f
c, d vs. e
e vs. f
TGFB1 1.00 1.06 -2.46 -4.90 -14.89 -1.30 a vs. b-e
b vs. d, e
e vs. c, d, f
COL5A2 1.00 1.15 -3.78 -4.27 -20.15 -2.68 a vs. b-f
b vs. d, e
e vs. c, d, f
COL12A1 1.00 -1.05 -2.49 -5.53 -10.87 -1.77 a vs. b-f
b vs. d, e
e vs. c, d, f
FOXC1 1.00 2.07 9.15 4.49 -1.74 2.89 a vs. b-f
b, c vs. d, e
e vs. d, f
LAMC1 1.00 -1.08 -1.61 -3.77 -8.55 -1.26 a vs. b-f
d vs. b, c
e vs. b-d
PDGFRA 1.00 -1.12 -1.76 -2.79 -2.40 -1.49 a vs. b-f
b vs. d, e
c vs. d
TGFB2 1.00 -1.49 -1.36 -3.73 -6.23 -1.76 a vs. b-f
b, c, f vs. d, e
Up- and down-regulated overlapping genes within life stage groups being significantly different from prepubertal animals at P \ 0.05. Pairwise
Comparisons at Padj \ 0.05 were made, and the relevant results are presented in the text
Table 4 continued
Prepubertal
(a)
Adolescent
(b)
Adult luteal
(c)
Pregnant
(d)
Lactating
(e)
Postmenopausal
(f)
Pairwise comparisons
Padj \ 0.05
IGF1 1.00 1.28 -2.46 -2.22 -8.22 -2.28 a vs. b-f
b vs. d-f
e vs. c, d
e vs. f
CD61 1.00 -1.07 1.20 -1.20 1.27 -1.20 a vs. b-f
e vs. b-d, f
Up- and down-regulated overlapping genes within life stage groups being significantly different from prepubertal animals at P \ 0.05. Pairwise
comparisons at Padj \ 0.05 were made, and the relevant results are presented in the text
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SERF1A, IGFBP5, GTM3, and TGFB3, respectively
(Padj B 0.05). There was a significant difference between
lactating and pregnant mammary gene expression for
GSTM3, IGFBP5, TGFB3, and CENPA (Padj B 0.05).
Quantitative RT-PCR
Quantitative RT-PCR was also used to assess expression
levels of 14 key genes associated with estrogen, androgen,
and prolactin signaling and metabolism, which had shown
differential expression by microarray. Six of these showed
significant fold change in expression in adulthood com-
pared to prepuberty (Fig. 4). The genes were MKI67,
PRLR, AR, SULT, HSD17B1, and HSD17B2. We found that
expression profile of these genes among different life
stages was similar to that shown with microarray. Consis-
tent with our microarray results, MKI67 and PRLR were
up-regulated during adulthood and pregnancy. Expression
of AR was down-regulated in pregnancy and lactation.
Expression of SULT mRNA, encoding for the enzyme that
sulfates and thereby deactivates estrone, was diminished
during pregnancy, relative to other groups. Expression of
HSD17B1, which encodes a major estrogen biosynthetic
enzyme converting estrone to estradiol, was highest in
prepubertal animals. Conversely, mRNA for the enzyme
catalyzing the reverse reaction (HSD17B2) was more
abundant in adult life stages.
Discussion
Our data demonstrate distinct life stage-specific patterns of
gene expression during breast development. Simplified
examples of expression patterns are shown in Fig. 5. With
respect to mammary development during puberty, our
findings support previous observations that GH operating
via IGF-1, ovarian estrogens, and the respective receptors
are crucial for normal breast development [2].
Estrogen-regulated genes such as ESR1 and IGF1 were
found to be up-regulated during adolescence. The increase
in IGF1 was not accompanied by an increase in IGFBP1
that would hamper its proliferative activity by protein
binding. Other estrogen-regulated genes such as GREB1,
TFF1, and PGR(B) were elevated during pubertal stages
and decreased with advancing age. GREB1 is an ERa
target gene and ERa coactivator that regulates estrogen-
induced proliferation in BC cells. It is overexpressed in
ERa-positive BC by 3.5-fold compared to ERa-negative
BC [21]. TFFs are associated with mucin-secreting epi-
thelial cells and contribute to mucosal defense and healing.
TFF1 is expressed in approximately 50% of human breast
tumors and enhances anchorage-independent growth,
increased cell migration, and invasion [22]. As an estrogen-
induced protein, it indicates likely responsiveness to
endocrine treatment [23]. Progesterone via its receptor
PGR is essential for mammary lobuloalveolar
Table 6 Genes related to BC
Prepubertal
(a)
Adolescent
(b)
Adult luteal
(c)
Pregnant
(d)
Lactating
(e)
Postmenopausal
(f)
Pairwise comparisons
Padj \ 0.05
SERF1A 1.00 -1.55 -1.90 -4.46 -6.18 -1.46 a vs. b-f
b, c vs. d, e
e vs. f
GTM3 1.00 -1.20 -1.76 -1.62 -3.07 -1.42 a vs. b-f
e vs. b-d, f
PECI 1.00 -1.32 -1.64 -2.33 -1.80 -1.17 a vs. b-f
b vs. d, e
e vs. f
IGFB5 1.00 1.47 -1.15 -2.72 -8.67 -1.69 a vs. b-f
b vs. c-e
c vs. d, e
d vs. e
e vs. f
TGFB3 1.00 1.27 -1.20 -1.86 -5.58 -1.34 a vs. b-f
e vs. b-d, f
CENPA 1.00 1.45 2.08 1.63 -2.16 -1.45 a vs. b-f
c, d vs. e, f
e vs. f
Up- and down-regulated genes shared by adult life stage groups that were significantly different from prepubertal group at Padj \ 0.01. Pairwise
comparisons at Padj \ 0.05 were made, and the relevant results are presented in the text
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development. In virgin mammary gland, the A subtype of
PGR dominates [24]. The PGR B signaling pathway shares
regulatory cross-talk with other pathways such as RANKL
[25]. The ratio of PGR isoforms may have a regulatory
effect during development [26, 27]. PRLR expression has
implications beyond prolactin per se; placental lactogen
and primate growth hormones bind the PRLR [28, 29],
which results in the activation of various signaling path-
ways including Jak2/Stat5 [30, 31], Shc/Grb2/Ras/Raf/
Mek/MapK [32–34], and PKB/PI3 K [35–37].
Pregnancy-associated life stages markedly differed from
other life stages. Prolactin is a major driver of development
during pregnancy both directly and through stimulation of
ovarian progesterone production. These hormones induce
rapid and global proliferation of epithelial cells within the
ductal epithelium and developing alveoli. During the sec-
ond half of pregnancy, the cells of the alveoli differentiate
and polarize to form the secretory alveolar epithelium,
capable of milk production and secretion during lactation.
Withdrawal of ovarian and placental progesterone brings
about the onset of secretory activation [38]. Accordingly,
PRLR gene expression reached its maximum during
pregnancy and remained high during lactation in our study.
Similarly, gene expression of CSN1S1, one of the pre-
dominant phosphoproteins in milk, tremendously increased
during lactation. However, production of caseins is also
stimulated by cortisol [37]. Enzyme HSD11B1 catalyzes
the reduction of cortisone to active cortisol, and not sur-
prisingly, we found that HSD11B1 gene expression paral-
leled the increased production of milk proteins.
Ki67 PRLR
AR SULT
HSD17B1 HSD17B2
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Fig. 4 Gene expression measurements taken by qRT-PCR. Box plots
of the 6 out of 13 genes examined with significant overall ANOVA at
P \ 0.05. Significant pairwise differences are indicated by differing
symbols. P values for pairwise differences are \0.01 (MKI67, PRLR,
AR, and 17BHSD2), \0.03 (17BHSD1), or \0.05 (SULT)
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During postmenopause, expression of various genes
came back to adult luteal level (STS, HSD11B1,
HSD17B7, HSD17B2, TFF1, GREB1, CSN1S1, IGFBP1,
NEK10, IGHG1, LRRN3, PPM1K, PGR, ESR1, PRLR,
AR). However, since the animals in this study were
imported from abroad where they had lived in a breeding
colony, it is likely that they had been pregnant before.
Therefore, the gene ‘‘thumb print’’ of past pregnancy may
be still present in our adult luteal subgroup.
AR gene expression decreased across life stage. AR
rapidly modulates the expression of genes involved in
proliferation and differentiation. Only recently, short-term
androgen treatment has been shown to diminish the estro-
gen-induced proliferative response of the breast in rhesus
monkeys [39, 40]. Furthermore, there is emerging evidence
that the androgen-signaling pathway plays a critical role in
breast carcinogenesis, independent of ER. In humans,
although hyperandrogenemia is thought to be a risk factor
for BC, expression of AR in BC is associated with lower
tumor burden and favorable differentiation [41].
Breast tissue and mammary cancer cells possess the
enzymatic systems necessary for local biosynthesis of
steroid hormones, including enzymes involved in both the
activation (STS, HSD11B1, HSD17B7) and inactivation
(HSD17B2, AKR1C4) of hormones. The increase in
ovarian serum estrogens during puberty and even more
during pregnancy was accompanied by a decrease in
mammary STS and HSD17B7 and an increase in
HSD17B2 favouring the formation of estrone, estrone
sulfate, and estriol. This control mechanism may protect
the mammary gland from excessive estrogenic exposure.
Indeed, HSD17B2 has been shown to be the predominant
HSD17B subtype in normal breast tissue, whereas in can-
cerous tissue, the ratio of HSD17B1 to HSD17B2 changes,
leading to a higher amount of locally formed potent
estradiol [42]. Similarly, STS activity is significantly
higher in cancerous in comparison with normal breast tis-
sue [43].
There is evidence for a hierarchical model in which all
types of epithelial cells in the mammary gland originate
from a common multipotent stem cell [6]. In this model,
ERa-negative stem cells (CD24?/CD29hi) undergo asym-
metric division to give rise to undifferentiated, ERa-posi-
tive progenitor cells. These multipotent progenitor cells
may also differentiate into basal-restricted or luminal-
restricted progenitors and alveolar-restricted lineages
(CD61?). During pregnancy, prolactin-mediated GATA3
may contribute to alveolar cell development, whereas
ELF5, also a target of prolactin signaling, establishes the
secretory alveolar lineage [44].
Across life stages, we found a significant increase in
CD24 and ALDH1 gene expression, which was highest
during lactation; this seems to indicate an amplification of
uncommitted progenitor cells during breast development
but may also indicate a lack of specificity for these putative
stem cell markers in the context of the mature breast.
Further differentiation to CD61-expressing luminal pro-
genitors mainly occurred during adult luteal and lactating
life stages. We also found an increase in ELF5 gene
expression across life stages, reaching a maximum during
adult luteal and lactating mammary gland, respectively,
thus paralleling CD61 and PRLR gene expression. As
mentioned above, GATA3 regulates mammary cell fate at
multiple time points throughout mammary gland develop-
ment including embryonic stage. Thus, it is not surprising
that we did not find a significant impact of the life stages
examined when using prepubertal animals as a reference of
comparison (data not shown).
The association of ALDH1 and BRCA1, which has
well-established roles in DNA repair and chromosome
stability, has been investigated by Wicha et al. [45]. They
suggest that BRCA1 plays a role in the differentiation of
ALDH1-positive/ER-negative stem/progenitor cells into
ERa-positive luminal epithelial cells. A loss of BRCA1
function may therefore cause a block in epithelial cell
differentiation and the expansion of undifferentiated, ER-
negative stem cells. BRCA1 expression was highest early
in life and reduced in pregnancy, lactation, and postmen-
opausal phases, with a nadir during lactation.
There is a variety of stem cell markers generally asso-
ciated with cell differentiation, repair mechanism, and
apoptosis, which displayed different gene expression pat-
terns across life stages. The majority of stem cell markers
analyzed revealed a decrease in gene expression
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Fig. 5 Schematic illustration of predominant patterns of gene
expression from the microarray data. Y axis is not to scale
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immediately with the transition into puberty (DICER1,
RIF1, BMPR1A, TGFB2, LIG4, KLF4, NOTCH2,
FOXA1), while others decreased after puberty (IGF1,
KLF4, POSTN, NOTCH2, LIG4). Some of them have been
investigated in BC. For example, DICER1 is thought to be
involved in tumorigenesis. Its down-regulation may be
related to the metastatic spread of tumors [46]. The IGF
pathway has also been linked to mammary carcinogenesis
in animal models. Higher IGF1 circulating levels signifi-
cantly increased cancer risk, including premenopausal BC
[47]. Other genes that were differentially expressed in our
animals have uncertain relevance. For example, KLF4 may
act as a transcriptional activator or repressor depending on
the promoter context and/or cooperation with other tran-
scription factors. There is no consensus on whether KLF4
functions as a tumor suppressor or an oncogene in BC
[48–50]. Similarly, the role of STAT5A/B in BC is com-
plex. In early stages of BC, STAT5A/B may promote
malignant transformation and enhance growth of the tumor.
This is in contrast to established BC, where STAT5A/B
may mediate the critical cues for maintaining differentia-
tion [51]. TGFB2 as part of the TGF-beta pathway is
generally antiproliferative in epithelial cells but can also
play either a tumor-suppressing or a tumor-promoting role
in human breast carcinogenesis, depending on age and
pathologic features of prognostic significance [52]. LIG4
encoding the protein DNA ligase IV that is involved in
double-strand break repair has been shown either to have
no significant relationship to BC risk [53, 54] or to be
associated with a decrease in BC risk [55].
For other so-called BC stem cell markers, only sparse
data are available so far. RIF1 contributes to ATM-medi-
ated protection against DNA damage. There is some evi-
dence that chromosome rearrangements such as RIF1 play
an important role in BC development [56]. There are some
links between BC and the transcriptional factor FOXA1,
[57] NEK10, [58], and NOTCH2 [59].
The IGHG1 protein has been shown to be down-regu-
lated in BC, [60] whereas ELF5 was expressed at higher
levels in BC cells than normal epithelial cells [61]. GATA3
has been shown to drive invasive BC cells to undergo
reversal of epithelial–mesenchymal transition, leading to
the suppression of cancer metastasis [62]. To date, there are
no data available on BC and BMPR1A, or LRRN3.
Extracellular matrix (ECM) molecules may provide
important clues regarding the differentiation and biologic
behavior of normal and neoplastic breast tissue. The high
expression of POSTN seen in the adolescent breast in this
study is interesting in light of the observation that POSTN
overexpression in BC is associated with the development
of bony metastases [63]. It may that the abnormal re-
expression of this developmentally expressed protein con-
tributes to the bone tropism of metastatic BC. Variations in
other ECM molecules are less profound and may be
explained at least in part by the relative proportions of
stroma to glandular tissue in the tissues examined.
Diagnostic molecular tools have the potential to help
clinicians decide how to treat a growing population of
patients with early-stage BC. The MammaPrint assay,
developed in 2001 at the Netherlands Cancer Institute in
Amsterdam, provides an expression profile of breast
tumors for BC prognosis and prediction. The signature
includes 70 relevant genes covering the hallmarks of can-
cer: cell cycle, metastasis, angiogenesis, and invasion [20].
In our data set, we found six genes covered by the Mam-
maPrint to be significantly regulated across life stages.
GSTM3, PECI, TGFB3, IGFBP5, and SERF1A gene
expression was reduced with advancing age, whereas
CENPA gene expression increased until pregnancy fol-
lowed by a significant decrease during lactation and post-
menopause. Glutathione S-transferases such as GSTM3
metabolize a broad range of xenobiotics and carcinogens
[64]. PECI is an auxiliary enzyme that catalyzes an isom-
erisation step required for the beta-oxidation of unsaturated
fatty acids [65]. Expression of SERF1A, IGFB5, and the
centromeric protein CENPA [66] is down-regulated in
tumor tissue [20]. The function of SERF1A has not been
elucidated yet.
This is the first study to investigate gene expression
profiles in normal breast tissue across life stages. Our data
demonstrate distinct patterns of gene expression during
breast development and may shed light on the profound
effect of reproductive life history on BC risk.
There has not been performed a comparable study in
humans so far. In the mouse model, comparative gene
expression analysis has focused on pregnancy, lactation,
and involution after weaning [67–69]. Broader assessments
across the lifespan have not been reported. In the murine
gland, PCA across pregnancy, lactation, and involution
revealed three distinct gene expression profiles with the
majority of genes being associated with the ‘‘proliferation’’
profile during late pregnancy, stable expression during
lactation, and diminished expression during involution
[68]. Gene ontology analysis showed that biological pro-
cesses such as ion transport, calcium-mediated signaling,
transferase activity, and cell proliferation were mostly
represented by the dominant ‘‘proliferation’’ PCA [68].
When focusing on single gene groups, adipocyte specific
genes (fat specific protein 27, resistin, adiponectin, CAP,
perilipin, hormone stimulated lipase, mitochondrial,
dicarboxylic amino acid transporter) were shown to decline
throughout pregnancy and early lactation, while milk pro-
tein genes (e.g., various caseins, mucin 1, a-lactalbumin,
butyrophilin, xanthine oxireductase, parathyroid hormone
related protein) increased over the time period. These
findings are in agreement with our data. Genes associated
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with the regulation of glucose entry and utilization for
lactose synthesis were mostly up-regulated at parturition
(e.g., glucose transporter 1, citrate synthase, citrate trans-
porter, ATP citrate lyase). Similarly, many genes that
determine the nature of the fatty acids in the triglyceride
were up-regulated at secretory activation [67, 70]. In their
model of secretory activation, Rudolph et al. suggested a
positive regulatory role for prolactin and the PRLR sig-
naling pathway via Akt1 (fatty acid synthesis, lactose
synthesis) and STAT5 (protein synthesis), while proges-
terone was thought to act as a negative regulator via direct
prolactin inhibition and indirectly by IGFBP5, TGFB2, and
Wnt5b signaling [68]. Similarly, our data showed a con-
stantly high expression of PRLR, STAT5, and ELF5 during
pregnancy and lactation, while the expression of the neg-
ative regulator TGFB2 and IGFBP5 was lowest during
lactation.
The study described here has its limitations. Since this is
an exploratory study design, many questions regarding
single gene function cannot be answered. Furthermore, as
mentioned above, since adult animals in this study were
obtained as adults from a breeding colony, they are likely
multiparous. The tissues examined were composed of a
variety of cell types, and the proportions of tissues varied
across the lifespan. Thus, some effects, such as the rela-
tively high expression of collagens in the juvenile stages,
likely represent the preponderance of fibroblasts in the
tissue sampled.
Most interestingly, a variety of genes including BC stem
cell genes currently discussed as potential biomarkers are
expressed already early in life. Thus, one might speculate
that, firstly, some developmental markers presented here
may also serve as biomarkers in BC; secondly, most genes
expressed later in life when BC risk is higher have already
been expressed during pubertal breast development sug-
gesting a ‘‘thumb print’’ of life events in breast tissue,
which, thirdly, leads to the hypothesis that exposure to
agents early in life (hormones, environmental and dietary
factors, etc.) may alter the gene expression profile of the
breast, thereby altering BC risk later in life.
Conclusion
Our data demonstrate distinct patterns of gene expression
during breast development. Several of the pathways acti-
vated during pubertal development have been implicated in
cancer development and metastasis, suggesting that
developmental signals may have application as biomarkers
for BC in later life. These data also illuminate imprinting
effects in early life, as many genes associated with early
breast differentiation persisted into later life. Possibly,
therapeutic interventions early in life may alter BC risk
later in life.
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